Regardless of what adjunctive strategies we employ, all
persistent lesions require evaluation and never “watchful waiting.” Failure to investigate further can result in advanced stage
discovery, more complex treatment protocols, compromised
quality of life, and even death.
The value in opportunistic screening has been proven time
and again. First and foremost, all adult patients should receive
a comprehensive extraoral and intraoral examination at least
With the acquired knowledge of risk behaviors and prevention strategies, our profession is strategically positioned to play
an integral role in earlier discovery of an abnormal lesion. The
impact of earlier discovery is far reaching and one of the most
gratifying aspects of our profession.
1. American Cancer Society. Cancer Facts & Figures 2017.
3. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal
cancer. Oral Oncology 45 (2009) 309–316.
4. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Gillison ML, et al.
Worldwide trends in incidence rates for oral cavity and oropharyngeal
cancers. J Clin Oncol. 2013 Dec 20; 31( 36): 4550-4559.
5. Jornet PL, Garcia FJ, Berdugo ML, Perez FP, Lopez AP. Mouth self-examination in a population at risk of oral cancer. Aust Dent J. 2015
Mar; 60( 1): 59-64.
7. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in
oropharyngeal cancer: the basics to know in clinical practice. Acta
Otorhinolaryngologica Italica. 2014; 34( 5):299-309
8. American Cancer Society. Cancer Treatment & Survivorship Facts &
Figures 2016-2017. Atlanta: American Cancer Society; 2016.
9. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival
of patients with oropharyngeal cancer. N Eng J Med. 2010; 363: 24-35.
11. National Cancer Institute. Surveillance, Epidemiology and End Results
Program. Cancer Stat Facts: Oral and Pharynx Cancer. https://seer.
12. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014 May; 50( 5): 380–
14. Saraiya M, Unger ER, Thompson TD, et al. HPV Typing of Cancers
Workgroup. US assessment of HPV types in cancers: implications for
current and 9-valent HPV vaccines. Journal of the National Cancer
15. CDC (Centers for Disease Control and Prevention) Genital HPV
Infection - Fact Sheet.
16. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM,
Westra WH, Gillison ML. Case-control study of human papillomavirus
and oropharyngeal cancer. N Engl J Med. 2007 May 10; 356( 19):1944-
17. GillisonML. Human papillomavirus-related diseases: oropharynx
cancers and potential implications for adolescent HPV vaccination. J
Adolesc Health. 2008; 43:S52-60.
19. Ferrer R. Lymphadenopathy: differential diagnosis and evaluation.
University of Texas Health Sciences Center at San Antonio, San
Antonio, Texas. Am Fam Physician. 1998 Oct 15; 58( 6):1313-1320.
20. Epstein J, Guneri P, Boyacioglu H, Abt E. The limitations of the
clinical oral examination in detecting dysplastic oral lesions and
oral squamous cell carcinoma. The Journal of the American Dental
Association. December 1, 2012. Vol. 143 no. 12;1332-1342.
21. Epstein JB, Gorsky M, Cabay RJ, Day T, Gonsalves W. Screening
for and diagnosis of oral premalignant lesions and oropharyngeal
squamous cell carcinoma: role of primary care physicians. Can Fam
Physician 2008; 54( 6):870-875.
22. Jemal A, Murray T, Samuels A, Chafoor A, Ward E, Thun MJ. Cancer
statistics, 2003. CA Cancer J Clin 2003; 53( 1): 5-26.
23. Mehrotra R, Mishra S, Singh M, Singh M. The efficacy of oral brush
biopsy with computer-assisted analysis in identifying precancerous
and cancerous lesions. Head and Neck Oncol. 2011, 3: 39. http://www.
24. Truelove E L, Dean D, Maltby S, et al. Narrow band (light) imaging of
oral mucosa in routine dental patients. Part 1: Assessment of value in
detection of mucosal changes. Gen Dent July/August 2011: p.281-89.
25. Laronde DM, Williams PM, Hislop TG, et al. Influence of fluorescence
on screening decisions for oral mucosal lesions in community dental
practices. J Oral Pathol Med (2013).
26. Kondori I, Mottin RW, Laskin DM. Accuracy of dentists in the clinical
diagnosis of oral lesions. Quintessence Int 2011; 42:575–7.
27. Poh CF, Anderson DW, Durham JS, et al. Fluorescence visualization–
guided surgery for early-stage oral cancer. JAMA Otolaryngol Head
Neck Surg. 2016;142( 3):209-216. doi: 10.1001/jamaoto.2015.3211
Published online January 14, 2016.
The author acknowledges the Canadian Dental Hygienists
Association for their contribution of images depicting the
extraoral and intraoral examination and the BC Oral Cancer
Prevention Program for their contributions.
We encourage your comments on this or any Penn Well course.
For your convenience, an online feedback form is available at
Jo-Anne Jones, RDH, is a well-recognized international
speaker, consultant, author and successful entrepreneur. She is
a Key Opinion Leader for several leading corporations within
the dental community. She has been described as a very dynamic, knowledgeable and authentic speaker with an ability
to powerfully communicate her knowledge. Jo-Anne proudly
partners with the Oral Cancer Foundation in conveying the
urgent need for changing the way in which we screen for oral
cancer to meet the needs of today’s population.
Jo-Anne Jones, RDH, is a key opinon leader for DenMat Hold-